Abstract

Over the past five years, the therapeutic landscape of type 2 diabetes mellitus (T2DM) has expanded with the 
emergence of novel pharmacotherapies targeting diverse pathophysiological pathways. These agents, including 
incretin-based therapies, dual and triple receptor agonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors, 
hepatokine modulators, and islet-targeted strategies, allow for individualized treatment approaches aimed at 
improving glycemic control, mitigating cardiovascular and renal risks, and addressing obesity-related 
complications. Advances in pharmacodynamics, pharmacokinetics, and biomarker-guided therapy facilitate 
personalized medicine, while combination therapies and fixed-dose regimens enhance efficacy and adherence. 
Clinical trial data support the safety and cardiometabolic benefits of these agents across diverse populations. 
Implementation in clinical practice requires careful patient selection, dose optimization, and monitoring, 
particularly in special populations with comorbidities. Overall, these novel pharmacotherapies provide promising 
tools to improve metabolic outcomes, delay disease progression, and reduce long-term complications in patients 
with T2DM.